Choose a language and wait for the translated text.
Shots:
Erasca has reported updated US P-I monotherapy & initial combination data of its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors, along with initial P-I monotherapy data of its pan-KRAS inhibitor ERAS-4001
In 2L+ KRAS G12X PDAC at 32mg QD, confirmed ORR was 44% (N=25) & 69% in KRAS G12D/G12V PDAC (N=13); in post-ICI/platinum KRAS G12X NSCLC, cORR was 60% (N=5) at 32mg QD & 58% (N=12) across 16-32mg QD; in KRAS G12X BTC, cORR was 75% (N=4). At 32mg QD (N=54), there were no DLTs or discontinuations due to TRAEs
Erasca plans to start a potentially registration-enabling trial in 2L+ lung cancer in H1’27, a P-III trial in 1L lung cancer in H2’27-H1’28 & has accelerated a P-III trial in 1L pancreatic cancer to H1’27; dose escalation of ERAS-0015 + ERAS-4001 is expected to start in 2027
Ref: GlobeNewswire | Image: Erasca | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Erasca Reports Updated P-I (AURORAS-1) Data of ERAS-0015 for RAS-Mutant Solid Tumors appeared first on PharmaShots.